Conatus Acquires Idun's Assets
This article was originally published in Start Up
Executive Summary
As it divests assets to restructure its research and development pipeline, Pfizer Inc. has found the best buyers are intimately familiar with what they're getting. In late July, the big pharma revealed it sold its Idun Pharmaceuticals Inc. subsidiary to Conatus Pharmaceuticals Inc., a startup founded by the same executives who led Idun prior to its nearly $300 million acquisition by Pfizer in 2005.